FDA clears IND application for novel dry eye disease therapy

The FDA has cleared an investigational new drug application for A197, which is being evaluated for the treatment of dry eye disease, according to a press release from Aramis Biosciences.

“We are pleased that FDA has cleared A197 to move into phase 2 clinical trials in dry eye patients. We believe that A197, with its novel mechanism of action targeting the immunopathogenesis of the disease and clean tolerability profile, has the potential to significantly improve the standard of care in dry eye disease,” David S. Tierney, MD, president and CEO of Aramis Biosciences, said in the release.

Sign outside FDA HQ in Washington, DC. — *Source: Adobe Stock*

Aramis plans to begin a phase 2 proof of concept clinical trial investigating A197 in the first quarter.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

FDA clears IND application for novel dry eye disease therapy

Related Content